PTC Therapeutics (PTCT) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
PTC Therapeutics (PTCT) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, losing 1.1% versus a loss of 11.4%. Over five years, RYTM leads with a +682.1% price change compared with +66.0% for PTCT. Rhythm Pharmaceuticals is the larger company by market cap ($6.11 billion vs $5.22 billion), about 1.2 times the size, while PTC Therapeutics is growing revenue faster (+114.5% vs +45.8%).
PTC Therapeutics converts more of its revenue into profit, with a net margin of 39.4% versus -103.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTCT | RYTM |
|---|---|---|
| Share price | $62.54 | $88.78 |
| Market cap | $5.22B | $6.11B |
| 1-day change | -1.09% | +0.37% |
| YTD return | -16.76% | -17.37% |
| 1-year return | -1.06% | -11.40% |
| 5-year return | +66.00% | +682.05% |
| Forward P/E | 23.36 | — |
| EPS (TTM) | $-0.65 | $-3.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.73B | $189.76M |
| Revenue growth (YoY) | +114.51% | +45.83% |
| Net income (latest FY) | $682.64M | $-196.54M |
| Gross margin | — | 89.73% |
| Operating margin | 50.09% | -101.19% |
| Net margin | 39.44% | -103.57% |
| 52-week high | $90.87 | $122.20 |
| 52-week low | $61.23 | $74.50 |
| Distance from 52-week high | -31.18% | -27.35% |
| Analyst consensus | buy | none |
| Avg. price target upside | +62.76% | +56.10% |
| Average volume | 1.14M | 649.06K |
| Shares outstanding | 83.46M | 68.85M |
| Employees | 991 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTCT has outperformed RYTM by 10.3 percentage points over the past year.
- PTC Therapeutics is more profitable, keeping 39.4 cents of every revenue dollar as net income versus -103.6 cents for Rhythm Pharmaceuticals.
- PTC Therapeutics grew revenue faster in its latest fiscal year (+114.51% vs +45.83%).
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
PTCT vs RYTM FAQ
Which is bigger, PTC Therapeutics or Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) is larger, with a market capitalization of $6.11B compared with $5.22B for PTC Therapeutics (PTCT).
Which stock has performed better over the past year, PTCT or RYTM?
PTCT returned -1.06% over the past 12 months, compared with -11.40% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are PTC Therapeutics and Rhythm Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.